Although Canadian subjects had greater A1C reductions from baseline compared with US subjects ( p = 0.02 ) , the incremental benefit of SAP was similar in the US ( SAP compared with MDI,-0 .93 % 0.73 % vs.-0 .31 % 0.81 % , p < 0.001 ) and Canada ( -1.14 % 0.72 % vs.-0 .67 % 0.71 % , p < 0.001 ) .